Results 1 to 10 of about 97,231 (203)

Topical steroid withdrawal treated with ruxolitinib cream [PDF]

JAAD Case Reports
Moira Shea, BS, Erin Grinich, MD, Eric Simpson, MD, MCR   +2 more
doaj   +5 more sources

Ruxolitinib cream for the treatment of granuloma annulare [PDF]

JAAD Case Reports
Austin J. Piontkowski, BS, Nancy Wei, MD, Aisha Mumtaz, MD, Nicholas Gulati, MD, PhD   +3 more
doaj   +5 more sources

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo [PDF]

Dermatology and Therapy
Introduction Ruxolitinib cream demonstrated superior repigmentation versus vehicle at week 24 with continued improvement through week 104 in phase 3 studies of patients (aged ≥ 12 years) with nonsegmental vitiligo.
David Rosmarin, Amit G. Pandya, Thierry Passeron, Seth B. Forman, Jacek Zdybski, Mark Amster, Christina Feser, Kim A. Papp, Anthony Nuara, Deanna Kornacki, Shaoceng Wei, Haobo Ren, John E. Harris, Khaled Ezzedine   +13 more
doaj   +3 more sources

Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies [PDF]

Dermatology and Therapy
Introduction Two phase 3 trials (TRuE-V1 and TRuE-V2) demonstrated that a topical formulation of the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved repigmentation versus vehicle cream in adolescent and adult patients with vitiligo.
Julien Seneschal, Albert Wolkerstorfer, Seemal R. Desai, Pearl Grimes, Khaled Ezzedine, Amit G. Pandya, Deanna Kornacki, Shaoceng Wei, Thierry Passeron, David Rosmarin   +9 more
doaj   +3 more sources

Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication [PDF]

Therapeutic Advances in Chronic Disease
Summary What is this summary about? • This is a summary of a research article published in a medical journal that describes the main results from two studies called TRuE-V1 and TRuE-V2 • These studies looked at the use of ruxolitinib cream to treat ...
David Rosmarin, Thierry Passeron, Amit G. Pandya, Pearl Grimes, John E. Harris, Seemal R. Desai, Mark Lebwohl, Mireille Ruer‑Mulard, Julien Seneschal, Albert Wolkerstorfer, Deanna Kornacki, Kang Sun, Kathleen Butler, Khaled Ezzedine   +13 more
doaj   +3 more sources

Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and ...
Melinda J. Gooderham, H. Chih-ho Hong, Di Wang, Becky Hooper, Avery Hughes-Martin, Heather Cameron, Laura Pastor, Alicia Pepper, Ping Wu, Ali Mojebi, Grace Wong, Rafael Marino, Marie-Lise Dion, Mehdi Larbi   +13 more
doaj   +3 more sources

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream [PDF]

Pharmaceutics, 2021
Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple ...
Paul Smith, Wenqing Yao, Stacey Shepard, Maryanne Covington, Jim Lee, Jennifer Lofland, Ahmad Naim, Trupti Sheth, Bhavnish Parikh, Swamy Yeleswaram   +9 more
doaj   +5 more sources

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab [PDF]

JAAD Case Reports, 2023
Juna Khang, BA, J. Michael Yardman-Frank, MD, MPH, Li-Chi Chen, MD, MPH, Hye Jin Chung, MD, MMSc   +3 more
doaj   +5 more sources

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

New England Journal of Medicine, 2022
BACKGROUND Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo.
Thierry Passeron
exaly   +6 more sources

Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. [PDF]

Drugs
Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials,
Kang C.
europepmc   +4 more sources